BACKGROUND: Hypothalamic-pituitary-adrenal (HPA) axis function, as variously measured by the responses to the combined dexamethasone/corticotrophin-releasing hormone (dex/CRH) test, the dexamethasone suppression test (DST) and basal cortisol levels, has been reported to be abnormal in bipolar disorder. AIMS: To test the hypothesis that HPA axis dysfunction persists in patients in remission from bipolar disorder. METHOD: Salivary cortisol levels and the plasma cortisol response to the DST and dex/CRH test were examined in 53 patients with bipolar disorder, 27 of whom fulfilled stringent criteria for remission, and in 28 healthy controls. Serum dexamethasone levels were measured. RESULTS: Patients with bipolar disorder demonstrated an enhanced cortisol response to the dex/CRH test compared with controls (P=0.001). This response did not differ significantly between remitted and non-remitted patients. These findings were present after the potentially confounding effects of dexamethasone levels were accounted for. CONCLUSIONS: The dex/CRH test is abnormal in both remitted and non-remitted patients with bipolar disorder. This measure of HPA axis dysfunction is a potential trait marker in bipolar disorder and thus possibly indicative of the core pathophysiological process in this illness.
BACKGROUND:Hypothalamic-pituitary-adrenal (HPA) axis function, as variously measured by the responses to the combined dexamethasone/corticotrophin-releasing hormone (dex/CRH) test, the dexamethasone suppression test (DST) and basal cortisol levels, has been reported to be abnormal in bipolar disorder. AIMS: To test the hypothesis that HPA axis dysfunction persists in patients in remission from bipolar disorder. METHOD: Salivary cortisol levels and the plasma cortisol response to the DST and dex/CRH test were examined in 53 patients with bipolar disorder, 27 of whom fulfilled stringent criteria for remission, and in 28 healthy controls. Serum dexamethasone levels were measured. RESULTS:Patients with bipolar disorder demonstrated an enhanced cortisol response to the dex/CRH test compared with controls (P=0.001). This response did not differ significantly between remitted and non-remitted patients. These findings were present after the potentially confounding effects of dexamethasone levels were accounted for. CONCLUSIONS: The dex/CRH test is abnormal in both remitted and non-remitted patients with bipolar disorder. This measure of HPA axis dysfunction is a potential trait marker in bipolar disorder and thus possibly indicative of the core pathophysiological process in this illness.
Authors: Leandro L Valiengo; Márcio G Soeiro-de-Souza; Andrea H Marques; Doris H Moreno; Mário F Juruena; Ana Cristina Andreazza; Wagner F Gattaz; Rodrigo Machado-Vieira Journal: J Affect Disord Date: 2012-02-02 Impact factor: 4.839
Authors: M L Prieto; A B Cuéllar-Barboza; W V Bobo; V L Roger; F Bellivier; M Leboyer; C P West; M A Frye Journal: Acta Psychiatr Scand Date: 2014-05-22 Impact factor: 6.392